VNRX
VOLITIONRX LTDCompany Information
- Company Name
- VOLITIONRX LTD
- CIK
- CIK0000093314
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- VNRX: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2835
- SIC Description
- In Vitro & In Vivo Diagnostic Substances
- Ticker
- VNRX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-11-17
- Last sale
- 2024-01-02
- Shares purchased (TTM)
- 1,357,263
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,931,099
- Shares outstanding
- 12,044,339
- Ownership
- 16.03%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -44.44%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 3 | 3 | 1 | 0 | 2 | 3 | 3 | 5 | 6 | 12 | 21 | 11 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 4 | 5 | 2 | 1 | 3 | 3 | 4 | 7 | 7 | 13 | 22 | 12 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense Current | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 5 | 5 | 5 | 6 | 5 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Finite Lived Intangible Assets Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Assets | 8 | 9 | 7 | 6 | 9 | 9 | 9 | 13 | 13 | 19 | 28 | 18 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 4 | 4 | 3 | 3 | 2 | 3 | 3 | 2 | 3 | 4 | 3 | 3 | ||||||
| Accrued Liabilities Current | 3 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 3 | ||||||
| Deferred Revenue Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 23 | 23 | 0 | 10 | ||||||
| Management Fee Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 13 | 14 | 12 | 11 | 9 | 8 | 8 | 30 | 31 | 31 | 9 | 18 | ||||||
| Long Term Debt Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Contract With Customer Liability | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | 0 | 0 | 0 | - | 0 | - | ||||||
| Derivative Liabilities Current | 2 | 1 | 1 | 0 | 1 | - | 0 | - | - | - | - | - | ||||||
| Convertible Notes Payable Current | 3 | 3 | 2 | 2 | 0 | - | 0 | - | - | - | - | - | ||||||
| Long Term Debt Noncurrent | 6 | 6 | 6 | 6 | 6 | 6 | 4 | 4 | 4 | 3 | 4 | 2 | ||||||
| Deferred Revenue Noncurrent | 21 | 21 | 22 | 22 | 23 | 23 | 23 | - | - | - | - | - | ||||||
| Finance Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Long Term Notes Payable | 0 | 0 | 1 | 2 | 3 | - | 0 | - | - | - | - | - | ||||||
| Liabilities Noncurrent | 28 | 29 | - | 31 | 33 | 29 | - | 5 | 5 | 5 | - | 3 | ||||||
| Liabilities | 42 | 42 | 42 | 42 | 42 | 38 | 36 | 35 | 36 | 36 | 37 | 21 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 235 | 228 | 219 | 212 | 210 | 207 | 204 | 202 | 196 | 195 | 194 | 192 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -267 | -260 | -253 | -247 | -241 | -235 | -230 | -224 | -218 | -211 | -203 | -194 | ||||||
| Stockholders Equity | -34 | -33 | -34 | -36 | -33 | -28 | -26 | -23 | -22 | -16 | -8 | -2 | ||||||
| Minority Interest | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Liabilities And Stockholders Equity | 8 | 9 | 7 | 6 | 9 | 9 | 9 | 13 | 13 | 19 | 28 | 18 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 325 | 325 | 325 | 325 | 325 | 175 | 325 | 175 | 100 | 100 | 175 | 100 | ||||||
| Common Stock Shares Issued | 12 | 8 | 6 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | ||||||
| Shares Outstanding | 12 | 8 | 6 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVOLITIONRX LTD (VNRX) — SEC Financial Statements & Analysis
VOLITIONRX LTD (VNRX) is a in vitro & in vivo diagnostic substances company, incorporated in DE. VOLITIONRX LTD trades on NYSE as: VNRX. VOLITIONRX LTD (VNRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, VOLITIONRX LTD carries a market cap of $16.26M, a P/E ratio of -0.63x, a P/B ratio of -0.48x, a P/S ratio of 6.61x, an enterprise value of $23.99M, and an EV/EBITDA multiple of -1.29x. On profitability, it posts an operating margin of -790.22%, a net margin of -1044.25%, a Return on Equity (ROE) of 77.04%, and a Return on Assets (ROA) of -301.87%. Per share, it reports EPS of $-2.13, diluted EPS of $-2.80, free cash flow per share of $-1.63, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 86.32% year-over-year, net income growth of 10.06% year-over-year, and EPS growth of -52.49% year-over-year. On the balance sheet, it maintains a current ratio of 0.30x, a quick ratio of 0.25x, working capital of $-9.40M, a debt-to-equity ratio of -1.25x, a debt ratio of 5.04, an interest coverage ratio of -22.42x, free cash flow of $-19.58M (TTM), and net debt of $7.74M. Figures sourced from SEC EDGAR.
- Market Cap
- $16.26M
- P/E TTM
- -0.63x
- EPS TTM
- $-2.13
- P/B TTM
- -0.48x
- ROE TTM
- 77.04%
- ROA TTM
- -301.87%
- Debt To Equity
- -1.25x
- Free Cash Flow TTM
- $-19.58M
- Net Revenue TTM Growth 1Y
- 86.32%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is VOLITIONRX LTD in?
VOLITIONRX LTD (VNRX) operates in the In Vitro & In Vivo Diagnostic Substances industry.
What exchange does VNRX trade on?
VOLITIONRX LTD (VNRX) trades on the NYSE.
Where is VOLITIONRX LTD incorporated?
VOLITIONRX LTD is incorporated in DE.
When was VOLITIONRX LTD (VNRX)'s most recent SEC filing?
VOLITIONRX LTD (VNRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is VNRX's market cap?
VOLITIONRX LTD (VNRX) has a market capitalization of $16.26M as of 2026-06-30.
What is VNRX's EPS (earnings per share)?
VOLITIONRX LTD (VNRX)'s trailing twelve month EPS is $-2.13 as of 2026-06-30.
What is VNRX's ROE (return on equity)?
VOLITIONRX LTD (VNRX)'s trailing twelve month Return on Equity (ROE) is 77.04% as of 2026-06-30.
What is VNRX's ROA (return on assets)?
VOLITIONRX LTD (VNRX)'s trailing twelve month Return on Assets (ROA) is -301.87% as of 2026-06-30.
What is VNRX's EV/EBITDA?
VOLITIONRX LTD (VNRX)'s trailing twelve month EV/EBITDA is -1.29x as of 2026-06-30.